Clinical Trials Browser

NCT07001384 2026-05-26

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Phase 1 Recruiting

30 enrolled

Lymphoid

Lymphoma, Large-Cell, Anaplastic

NCT04302025 2026-05-22

NAUTIKA1

Phase 2 Recruiting

99 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03194893 2026-05-20

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Phase 3 Active not recruiting

200 enrolled

EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Multiple Endocrine Neoplasia Type 2a

NCT06765109 2026-05-14

ALKAZAR

Phase 3 Recruiting

450 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT07560410 2026-05-11

Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)

Phase 1/2 Not yet recruiting

10 enrolled

Sarcoma

Bone Neoplasms

NCT03202940 2026-05-08

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Phase 1/2 Active not recruiting

16 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Phase 2 Active not recruiting

920 enrolled 1 FDA

Other solid neoplasm

Solid Tumors

NCT05170204 2026-05-06

HORIZON 1

Phase 3 Active not recruiting

68 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03456076 2026-05-05

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

257 enrolled 14 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04774718 2026-05-05

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Phase 1/2 Recruiting

42 enrolled

CNS

Central Nervous System Neoplasms

NCT02314481 2026-05-04

DARWINII

Phase 2 Completed

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Genomic Instability

NCT03768063 2026-04-28

IMbrella B

Phase 3 Active not recruiting

1,000 enrolled

Tumor-Agnostic

Neoplasms

NCT04116541 2026-04-24

MegaMOST

Phase 2 Recruiting

455 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03737994 2026-04-23

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase 2 Terminated

10 enrolled 17 charts

Thoracic

Lung Neoplasms

NCT05713006 2026-04-08

Alectinib Pharmacokinetic in Patients With NSCLC

Phase 1/2 Recruiting

45 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05987644 2026-04-08

DURABLE

Phase 1/2 Recruiting

56 enrolled

CNSThoracic

Brain Neoplasms, Lung Neoplasms

NCT06624059 2026-04-08

HORIZON 2

Phase 1/2 Active not recruiting

11 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06354387 2026-03-19

Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

Phase 1 Completed

5 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT02838420 2026-03-18

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Active not recruiting

187 enrolled 14 charts

Thoracic

Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

NCT03178552 2026-03-09

B-FAST

Phase 2/3 Active not recruiting

1,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung